Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB
2025-09-09 20:54
Share Issue/Capital Change
English 8.2 KB
2025-09-09 20:54
Share Issue/Capital Change
English 175.5 KB
2025-08-12 20:36
Share Issue/Capital Change
English 175.2 KB
2025-08-12 20:36
Share Issue/Capital Change
English 7.8 KB
2025-08-07 17:08
Earnings Release
English 17.2 KB
2025-08-07 17:08
Earnings Release
English 741.7 KB
2025-08-07 16:30
Regulatory News Service
English 207.6 KB
2025-08-07 16:30
Legal Proceedings Report
English 21.0 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Labocanna Spolka Akcyjna Logo
Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.
Poland LCN
Labomar Logo
A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.
Italy LBM
Laboratorio Farmaceutico Erfo Logo
Full-service contract manufacturer of private label supplements and medical devices.
Italy ERFO
Laboratorio Reig Jofre S.A. Logo
A pharmaceutical company making essential health products accessible in over 70 countries.
Spain RJF
Laboratorios Farmaceuticos Rovi S.A. Logo
Integrated pharma firm developing prescription drugs and offering contract manufacturing services.
Spain ROVI
Lavipharm S.A. Logo
Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.
Greece LAVI
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden LPGO
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN

Talk to a Data Expert

Have a question? We'll get back to you promptly.